GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Net Change in Cash

BioNTech SE (BioNTech SE) Net Change in Cash : $-3,443 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BioNTech SE Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

BioNTech SE's Net Change in Cash for the three months ended in Mar. 2024 was $-2,921 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 was $-3,443 Mil.

BioNTech SE Net Change in Cash Historical Data

The historical data trend for BioNTech SE's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioNTech SE Net Change in Cash Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Change in Cash
Get a 7-Day Free Trial 119.56 840.76 545.20 12,905.09 -2,411.56

BioNTech SE Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,853.53 2,191.44 -715.90 -1,997.93 -2,920.76

BioNTech SE Net Change in Cash Calculation

BioNTech SE's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=5857.579+-7583.969+-849.073+163.904
=-2,412

BioNTech SE's Net Change in Cash for the quarter that ended in Mar. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-344.891+-2504.783+-8.478+-62.609
=-2,921

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3,443 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Net Change in Cash Related Terms

Thank you for viewing the detailed overview of BioNTech SE's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

BioNTech SE (BioNTech SE) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioNTech SE (NAS:BNTX) » Definitions » Net Change in Cash
Comparable Companies
BGNE ALNY MRNA BMRN RPRX LEGN INCY UTHR SRPT TECH OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 HKSE:02269 XBRU:ARGX SZSE:300122 OCSE:GMAB
Traded in Other Exchanges
BNTX:Mexico 0A3M:UK 22UA:Germany B1NT34:Brazil BNTX:Austria
Address
An der Goldgrube 12, Mainz, RP, DEU, D-55131
Website
https://www.biontech.de
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech SE (BioNTech SE) Headlines

From GuruFocus

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

By PRNewswire • 01-15-2024

BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda

By Marketwired • 12-18-2023

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

By Marketwired • 01-09-2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX

By PRNewswire • 01-16-2024

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action -- BNTX

By Business Wire • 01-16-2024

BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

By Marketwired • 10-19-2023

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

By Business Wire • 01-22-2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines - BNTX

By PRNewswire • 01-22-2024

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE

By PRNewswire • 01-21-2024

Update Regarding Pfizer's Statement on COMIRNATY-Related Write-Offs

By Marketwired • 10-16-2023